Thomas M. Birch, M.D.

718 Teaneck Road, Teaneck, NJ 07666

Phone: 201-833-7274| Fax: 201-833-7243 | E-mail: thomasbirch.md@gmail.com

 

 

Current Positions, July 1993 to present

  • Private practice of Infectious Diseases and Internal Medicine, Teaneck and Englewood New Jersey

  • Clinical Instructor, Internal Medicine, Mount Sinai College of Medicine, New York, NY

 

Hospital Affiliations:

  • Holy Name Medical Center, Teaneck, NJ    

  • Englewood Hospital and Medical Center, Englewood, NJ

  • Kessler Institute for Rehabilitation, Saddle River, NJ

 

Holy Name Medical Center

  • Medical Director and Founder, Institute for Clinical Research

  • President of the Medical Staff 2012-2014

  • Activities / Collaborations

    • Accountable Care Organization

    • Electronic Physician Newsletter

    • Computer Physician Order Entry

    • Complete New Medical Staff Bylaws

  • Successful Joint Commission Survey

  • Chief of the Section of Infectious Diseases 2004-2010

  • Chairman, Infection Prevention Committee

  • Member: Pharmacy and Therapeutics Committee

  • Chairman, of the Antibiotic Sub-Committee

  • Member: Performance Improvement, Physician Development, Patient Safety Committees

  • Member: Board of Trustees 2005-2010, 2011-2013

   

Previous Positions

  • Medical Director, Nyack Hospital Health Care Center 1988 to 1991

  • Medical Director, Business Health Services

  • Director of House Physicians, Nyack Hospital

  • Medical Director, Employee Health Service, Nyack Hospital

  • Clinical Assistant Professor of Medicine, New York Medical College

  • Clinical Instructor, Internal Medicine, Albert Einstein College of Medicine 1986 to 1988

  • Attending Physician, Department of Medicine, Montefiore Medical Center

  • Attending Physician, Departments of Medicine and Ambulatory Care, North Central Bronx Hospital

 

Certification and Licensure

  • Board Certified, Infectious Diseases, American Board of Internal Medicine 1994, Re-certified 2004 & 2014

  • Board Certified, Internal Medicine, American Board of Internal Medicine 1986, Unlimited Certificate

 

Licensure:  

  • New Jersey and New York

 

Education

  • Medical Doctor, University of Wisconsin, School of Medicine 1979 to 1983

  • Bachelor of Science, Biochemistry, University of Wisconsin-Madison, College of Letters and Science 1973 to 1977

 

Residency/ Fellowship Training:

  • Internship and Residency, Social Medicine Residency Program, Montefiore Medical Center, Bronx, NY July 1983 to June 1986

  • Infectious Diseases fellow, Albert Einstein College of Medicine July 1991 to June 1993

 

Research Experience

Investigator

  • A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study To Evaluate The Efficacy And Safety Of Iv And Oral Delafloxacin Compared With Vancomycin + Aztreonam In Patients With Acute Bacterial Skin And Skin Structure Infections

  • Clinical Protocol: Laboratory Use Method Comparison Studies for the NanoDetection Technology MRSA Direct Screen (Methicillin Resistant S. aureus) Test System

  • A Phase III Randomized Double-Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of Nitazoxanide and Nitazoxanide plus Oseltamivir in the Treatment of Acute Uncomplicated Influenza

  • A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared with Ertapenem in Complicated Intra-abdominal Infections

  • Efficacy, Immunogenicity, and Safety Study of Clostridium difficile - Vaccine in Subjects at Risk of C. difficile Infection

  • A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. difficile toxin B), and MK-3415A (Human Monoclonal Antibodies to C. difficile toxin A and B) in Patients Receiving Antibiotic Therapy for C. difficile Infection (MODIFY II)

  • A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous to Oral 6-Day TR-701 Free Acid and Intravenous to Oral 10-Day Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

  • A Multicenter, Double-blind, Randomized, Phase 3 Study to Compare the Efficacy and Safety of Intravenous CXA‑201 with that of Meropenem in Complicated Intraabdominal Infections

  • A Multicenter, Double-blind, Randomized, Phase 3 Study to Compare the Safety and Efficacy of Intravenous CXA‑101/tazobactam and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis/CXA-cUTI-10-04

  • Protocol 14595 - An open-label, non-randomized study to evaluated the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detectin/exclusion of cerebral β-amyloid when compared to post mortem histopathology

  • A Phase 2, multi-center, randomized, double-blind study comparing the safety and efficacy of two doses of BC-3781 versus vancomycin in patients with acute bacterial skin and skin structure infections.            Nabriva

  • Study Number 12839: MAGELLAN- Multicenter, randomized, parallel Group Efficacy and safety study for prevention of venous thromboembolism in hospitalized medically ill patients comparing rivaroxaban with enoxaparin.  Bayer

  • A Multinational, Multi-center, Randomized, Double-Blind study comparing the efficacy and safety of AVE5026 with enoxaparin for the primary prevention of Venous Thromboembolism on Acutely III medical patients with restricted mobility.  Sanofi-Aventis

  • A Phase 3, Multi-center, Placebo-controlled, randomized, double-blind study to evaluate the safety and efficacy of PROCHYMAL (ex vivo cultured adult human mesenchymal stem cells) intravenous infusion for the induction of remission in subjects experiencing treatment-refractory moderate to severe Crohn’s disease.   Osiris

  • A double-blind, randomized, controlled trial of Rifaximin compared to Vancomycin for the treatment of Clostridium Difficile Associated Diarrhea (CDCD).  Salix Pharma

  • A Phase 3, randomized, Investigator-Blind, Multi-Center study to evaluate efficacy and safety of intravenous Iclaprim versus intravenous Linesolid in complicated and skin structure infections (ASSIST-2)        Arpida

  • A Multi-center, randomized, double-blind, placebo-controlled trial of novel CCR5 antagonist, UK-427,857, in combination with optimized background therapy versus optimized background therapy alone for treatment of antiretroviral-experienced HIV-1 infected subjects.  Pfizer

  • A Phase 3, Multicenter, Open-Label. Historical comparative Study to Evaluate Immunogenicity and Safety of StaphVAX®, a Bivalent  Staphylococcus aureus Glycoconjugate Vaccine in Adults on Hemodialysis

  • Retrospective evaluation of metronidazole as primary prophylaxis of clostridium difficile colitis

  • Preceptor for internal medicine resident research projects on various topics

  • Assessing and reducing the nosocomial transmission of tuberculosis: Evaluation of early recognition, airborne isolation and Hospital Employee screening programs

  • Clinical Investigator, Investigational New Drug Protocol of Azidothymidine and for other anti-retrovirals for AIDS  Since 1987

  • Research Specialist, Department of Medicine, University of Minnesota Medical School Project: Biochemical characterization of the intermediate density lipoprotein of Type III hyperlipoproteinemia as part of the Lipid Research Clinics Study

 

Awards

  • Castle-Connolly: Best Doctors in New Jersey Elected by peers for Infectious Diseases Yearly 1999-2014

  • Leo M. Davidoff Award Outstanding Teaching of Medical Students

  • Gibbs Zauft Award Quality Patient Care

  • Mary Shine Peterson Scholarship_ 1975 & 1976 Biochemistry

 

Selected List of Lectures

  • Approach to the Patient with HIV/AIDS for Medical Residents, yearly, 1994 to 2005

  • Approach to the Patient with Infection Associated with Non-HIV Immunodeficiency or Immunosuppression for Medical Residents, yearly, 1995 to 2005

  • Antimicrobial Resistance in the Intensive Care Unit, Critical Care Conference, Englewood Hospital 10/30/97

  • Hepatitis C-Review of Current Knowledge for the Public, Holy Name Hospital 10/28/99

  • Anthrax and Bioterrorism- Panel presentation and discussion, Holy Name Hospital 11/21/02

  • Management of Antibiotic Use-Big Brother vs. Team Play, Medical Grand Rounds at Holy Name Hospital 1/28/00.

  • Antibiotic Management, Current Status, Roche Labs 5/18/00.

  • Update on Diagnosis and Treatment of Lyme Disease, Roche Labs 9/24/00.

  • Community Acquired Pneumonia, Medical Grand Rounds at Englewood Hospital 9/28/01

  • A Semi-Qualitative Method to Improve the Diagnosis of Lyme Disease, Medical Grand Rounds at Englewood Hospital 5/23/02

  • Voluntary Teams for Smallpox, Review of Disease and Vaccination, Grand Rounds at Holy Name Hospital 3/18/03

  • Severe Acute Respiratory Syndrome-SARS, Grand Rounds at Englewood Hospital 4/22/03

  • Severe Acute Respiratory Syndrome-SARS, Grand Rounds at Holy Name Hospital 5/15/03

  • Current Standards for Peri-Operative Prophylaxis of Wound Infection and Endocarditis, Department of Anesthesia at Holy Name Hospital 5/24/05

  • Clostridium Difficile Associated Diarrhea, Physicians’ Noon Talk at Holy Name Hospital 5/18/06

  • Clostridium Difficile, Grand Rounds at Holy Name Hospital 10/24/06

  • Complicated Skin and Skin Structure Infections, Physicians’ Noon talk at Holy Name Hospital 11/09/06

  • History Ecology & Implications of Antibiotic Resistance, OB/GYN Grand Rounds Holy Name Hospital 10/03/07

  • Manifestations of Entropy in Microbiology and Infection Control, Grand Rounds at Holy Name Hospital 9/23/08

  • Managing Infectious Diseases Prevalent in Sports, Sports Medicine Seminar, Grand Rounds at Holy Name Hospital 10/14/09

  • Infection Prevention and Clinical Research, Grand Rounds at Holy Name Medical Center 10/12/10

  • Clostridium Difficile: Controlling and preventing the most difficult healthcare associated infection, Grand Rounds at Holy Name Medical Center 5/24/11

  • Drugs, Diagnostics, and Devices: The Ways and Means of Clinical Research, Grand Rounds at Holy Name Medical Center 9/13/11

  • The Human Microbiome: Human-Microbiologic Ecology, Bergen County Libraries – February – March 2014

  • Commerce and Industry Association of New Jersey Healthcare Roundtable: “Clinical Research Breakthroughs in Healthcare: How Innovation is Improving Lives and Lowering Healthcare Costs”  January 2015

  • “Antimicrobial Stewardship: A Call to Action for Patient Safety” at the HNMC 2nd Annual Patient Safety Symposium on March 6, 2015